NEWS
AI Powers mRNA Race: AIM's mRNA RSV Vaccine Filed for US Clinical Trials
DeepSeek's global boom has driven a surge in Hong Kong-listed AI stocks, defying market trends. With the Hang Seng Tech Index soaring, AI stocks like Kingsoft Cloud and 4Paradigm have seen significant gains. Previously, Oracle founder Ellison described the "AI plus mRNA vaccine" scenario, sparking immense imagination about AI's potential in mRNA vaccine development.
On February 5, AIM Vaccines, a leading domestic vaccine company, announced that its mRNA RSV (Respiratory Syncytial Virus) vaccine, a blockbuster single-item vaccine in development, has been filed for clinical trials with the U.S. Food and Drug Administration (FDA). Preclinical data indicates that this vaccine demonstrates significantly higher humoral and cellular immune responses compared to internationally marketed products.
In prior performance announcements, AIM disclosed its use of AI for antigen structure analysis and mRNA sequence design in vaccine development. Beyond the RSV vaccine, AIM's mRNA platform encompasses multiple product pipelines, including mRNA vaccines for shingles, rabies, and influenza. This announcement underscores AIM's acceleration toward global markets by leveraging AI in the high-growth mRNA vaccine sector.
Currently, no RSV-specific antiviral drugs are approved for clinical use globally, making prevention a key strategy against RSV's health threats. While no RSV vaccine is approved in China, two global players, GlaxoSmithKline and Pfizer, dominate the market with combined 2023 sales reaching $2.46 billion. Industry advisor China Insights Consultancy (CIC) projects the global RSV vaccine market will expand to approximately $16.7 billion by 2030.
Oracle founder Ellison has publicly stated, "We can use AI to diagnose cancer through a simple blood test." Once we sequence the genes of cancer tumors, AI can design personalized mRNA vaccines within about 48 hours." AIM Vaccines, a domestic mRNA technology leader, is translating this vision into reality through exceptional R&D capabilities and forward-looking market strategies.
According to AIM’s latest announcement, in preclinical animal trials of its independently developed mRNA RSV vaccine, third-party test results showed that the vaccine’s specific IgG antibody titer, live virus neutralizing antibody potency, and specific T-cell immunity were all significantly higher than those of internationally marketed mRNA RSV control vaccines.
Huafu Securities' latest research report highlights the arrival of a global AI competition era, expressing optimism about the rise of Chinese large language models like DeepSeek, particularly in AI application and terminal deployment.
Thus, analysts believe that as AI technology advances and mRNA vaccine technology matures, their combination could bring boundless possibilities for vaccine R&D. AIM's mRNA technology platform is among the top domestically, with a robust mRNA vaccine R&D system. It has mastered the entire lifecycle of mRNA vaccine development and production. As a leading domestic mRNA vaccine company, AIM's explosive growth potential is self-evident with AI support.
On February 5, AIM Vaccines, a leading domestic vaccine company, announced that its mRNA RSV (Respiratory Syncytial Virus) vaccine, a blockbuster single-item vaccine in development, has been filed for clinical trials with the U.S. Food and Drug Administration (FDA). Preclinical data indicates that this vaccine demonstrates significantly higher humoral and cellular immune responses compared to internationally marketed products.
In prior performance announcements, AIM disclosed its use of AI for antigen structure analysis and mRNA sequence design in vaccine development. Beyond the RSV vaccine, AIM's mRNA platform encompasses multiple product pipelines, including mRNA vaccines for shingles, rabies, and influenza. This announcement underscores AIM's acceleration toward global markets by leveraging AI in the high-growth mRNA vaccine sector.
Currently, no RSV-specific antiviral drugs are approved for clinical use globally, making prevention a key strategy against RSV's health threats. While no RSV vaccine is approved in China, two global players, GlaxoSmithKline and Pfizer, dominate the market with combined 2023 sales reaching $2.46 billion. Industry advisor China Insights Consultancy (CIC) projects the global RSV vaccine market will expand to approximately $16.7 billion by 2030.
Oracle founder Ellison has publicly stated, "We can use AI to diagnose cancer through a simple blood test." Once we sequence the genes of cancer tumors, AI can design personalized mRNA vaccines within about 48 hours." AIM Vaccines, a domestic mRNA technology leader, is translating this vision into reality through exceptional R&D capabilities and forward-looking market strategies.
According to AIM’s latest announcement, in preclinical animal trials of its independently developed mRNA RSV vaccine, third-party test results showed that the vaccine’s specific IgG antibody titer, live virus neutralizing antibody potency, and specific T-cell immunity were all significantly higher than those of internationally marketed mRNA RSV control vaccines.
Huafu Securities' latest research report highlights the arrival of a global AI competition era, expressing optimism about the rise of Chinese large language models like DeepSeek, particularly in AI application and terminal deployment.
Thus, analysts believe that as AI technology advances and mRNA vaccine technology matures, their combination could bring boundless possibilities for vaccine R&D. AIM's mRNA technology platform is among the top domestically, with a robust mRNA vaccine R&D system. It has mastered the entire lifecycle of mRNA vaccine development and production. As a leading domestic mRNA vaccine company, AIM's explosive growth potential is self-evident with AI support.
